The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $787,793 Project Grant to the Regents of the University of Minnesota to conduct research on "LEVERAGING TARGETED BIOLOGICAL COMPLEXES TO MAXIMIZE NATURAL KILLER CELL IMMUNOTHERAPY IN LUNG CANCER". The three-year award, running from July 1, 2024 to June 30, 2027, will support the university's efforts to develop innovative immunotherapy approaches for treating lung cancer, with a focus on harnessing natural killer cell-based therapies. As a leading research institution, the University of Minnesota will leverage its extensive facilities, faculty expertise, and scientific capabilities to advance this critical military medical research initiative.
Generated 3/4/25, 7:33 AM